Together, patient samples of DLBCL, follicular lymphoma, and marginal zone lymphoma were sensitive to combination treatments of venetoclax plus BCLXi or MCL1i, showing cooperative effects with two BCL2 family inhibitors. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.